Lymphocyte subset abnormalities in early severe scleroderma favor a Th2 phenotype and are not altered by prior immunosuppressive therapy.

Ankoor ShahJan StorekRob WoolsonAshley PinckneyLynnette Keyes-ElsteinPaul K WallaceGregory D SempowskiPeter McSweeneyMaureen D MayesLeslie CroffordM E CsukaKristine PhillipsDinesh KhannaRobert SimmsKaren BallenSharon LeClercqWilliam St ClairAndrew B NixonRichard NashMark WenerRichard BrasingtonRichard SilverLinda M GriffithDaniel E FurstEllen GoldmuntzKeith M Sullivan

Published in: Rheumatology (Oxford, England) (2022)

ClinicalTrials.gov (https://clinicaltrials.gov), NCT00114530.

Keyphrases

systemic sclerosis
early onset
interstitial lung disease
peripheral blood
rheumatoid arthritis
drug induced
mesenchymal stem cells